Treatment of Hypertension with Propranolol

When used in the treatment of hypertension propranolol is at least of similar potency to bethanidine, guanethidine, and methyldopa. Propranolol does not produce postural or exercise hypotension and it seems that it is often more acceptable to patients than conventional drugs. It usually produces the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ 1969-01, Vol.1 (5635), p.7-16
Hauptverfasser: Prichard, B. N. C., Gillam, P. M. S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 16
container_issue 5635
container_start_page 7
container_title BMJ
container_volume 1
creator Prichard, B. N. C.
Gillam, P. M. S.
description When used in the treatment of hypertension propranolol is at least of similar potency to bethanidine, guanethidine, and methyldopa. Propranolol does not produce postural or exercise hypotension and it seems that it is often more acceptable to patients than conventional drugs. It usually produces the best control of the supine blood pressure. A series of 109 hypertensive patients was treated with propranolol; in nine the drug was withdrawn. In 92 of the patients a supine or standing blood pressure of 100 mm. Hg or less was achieved. Eighty of the patients had previously been treated with other potent drugs, and close comparisons and prolonged follow-up in 17 patients showed that diastolic pressures of 100 mm. Hg or less were achieved in more patients after propranolol than with guanethidine, bethanidine, or methyldopa. Sensitivity to propranolol varies widely, and dosage should be increased gradually. The hypotensive effect often takes six to eight weeks to reach its maximum. Propranolol reduces cardiac output but may also act by reducing the cardiac component of pressor stimuli; as a result the baroreceptors gradually regulate the blood pressure at a lower level. It is contraindicated in patients with obstructive airways disease or in uncompensated heart failure.
doi_str_mv 10.1136/bmj.1.5635.7
format Article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1981816</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>20395359</jstor_id><sourcerecordid>20395359</sourcerecordid><originalsourceid>FETCH-LOGICAL-b499t-26de9d12c2bd6c57fddaee222d17bd43464743b6dbf14c5863cb80564a3970373</originalsourceid><addsrcrecordid>eNp9kM9LwzAYhoMoc8zdvAoDD4LY2S8_m4sgw6kg6mGKt5A2qevcmpl06v57WzqmXjyF8Dy838uL0CHEQwDCz9PFbAhDxgkbih3UBcqTiCWE7KJuHMciAkrFPuqHMKu_mIhEctpBHSY4SKBddDrxVlcLW1YDlw9u1kvrK1uGwpWDz6KaDh69W3pdurmbH6C9XM-D7W_eHnoaX01GN9Hdw_Xt6PIuSqmUVYS5sdIAznBqeMZEboy2FmNsQKSGEsqpoCTlJs2BZizhJEuTmHGqiRQxEaSHLtrc5SpdWJPV3byeq6UvFtqvldOF-kvKYqpe3YcCmUACvA443gR4976yoVIzt_Jl3VmBEBwz4Elz5qy1Mu9C8DbfXoBYNduqelsFqtlWNfrR71ZbebPkD5-FyvktxjGRjDBZ86jlRajs15Zr_6a4IIKp--eRehk_3strgRWr_ZPWb1r82-wb41WZyg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776251687</pqid></control><display><type>article</type><title>Treatment of Hypertension with Propranolol</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>PubMed Central</source><creator>Prichard, B. N. C. ; Gillam, P. M. S.</creator><creatorcontrib>Prichard, B. N. C. ; Gillam, P. M. S.</creatorcontrib><description>When used in the treatment of hypertension propranolol is at least of similar potency to bethanidine, guanethidine, and methyldopa. Propranolol does not produce postural or exercise hypotension and it seems that it is often more acceptable to patients than conventional drugs. It usually produces the best control of the supine blood pressure. A series of 109 hypertensive patients was treated with propranolol; in nine the drug was withdrawn. In 92 of the patients a supine or standing blood pressure of 100 mm. Hg or less was achieved. Eighty of the patients had previously been treated with other potent drugs, and close comparisons and prolonged follow-up in 17 patients showed that diastolic pressures of 100 mm. Hg or less were achieved in more patients after propranolol than with guanethidine, bethanidine, or methyldopa. Sensitivity to propranolol varies widely, and dosage should be increased gradually. The hypotensive effect often takes six to eight weeks to reach its maximum. Propranolol reduces cardiac output but may also act by reducing the cardiac component of pressor stimuli; as a result the baroreceptors gradually regulate the blood pressure at a lower level. It is contraindicated in patients with obstructive airways disease or in uncompensated heart failure.</description><identifier>ISSN: 0007-1447</identifier><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1468-5833</identifier><identifier>DOI: 10.1136/bmj.1.5635.7</identifier><identifier>PMID: 5761914</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Average age ; Blood pressure ; Blood Pressure - drug effects ; Cardiac Output - drug effects ; Cardiac output determination ; Diuretics ; Dosage ; Female ; Guanethidine - therapeutic use ; Guanidines - therapeutic use ; Humans ; Hypertension ; Hypertension - drug therapy ; Hypotension - chemically induced ; Left ventricular hypertrophy ; Male ; Methyldopa - therapeutic use ; Middle Aged ; Papers and Originals ; Physical Exertion ; Physicians ; Placebos ; Posture ; Pressoreceptors - physiology ; Pressure pulses ; Propranolol - administration &amp; dosage ; Propranolol - adverse effects ; Propranolol - therapeutic use ; Valsalva Maneuver</subject><ispartof>BMJ, 1969-01, Vol.1 (5635), p.7-16</ispartof><rights>Copyright 1969 British Medical Journal</rights><rights>Copyright BMJ Publishing Group LTD Jan 4, 1969</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b499t-26de9d12c2bd6c57fddaee222d17bd43464743b6dbf14c5863cb80564a3970373</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/20395359$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/20395359$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,803,885,27924,27925,53791,53793,58017,58250</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/5761914$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prichard, B. N. C.</creatorcontrib><creatorcontrib>Gillam, P. M. S.</creatorcontrib><title>Treatment of Hypertension with Propranolol</title><title>BMJ</title><addtitle>Br Med J</addtitle><description>When used in the treatment of hypertension propranolol is at least of similar potency to bethanidine, guanethidine, and methyldopa. Propranolol does not produce postural or exercise hypotension and it seems that it is often more acceptable to patients than conventional drugs. It usually produces the best control of the supine blood pressure. A series of 109 hypertensive patients was treated with propranolol; in nine the drug was withdrawn. In 92 of the patients a supine or standing blood pressure of 100 mm. Hg or less was achieved. Eighty of the patients had previously been treated with other potent drugs, and close comparisons and prolonged follow-up in 17 patients showed that diastolic pressures of 100 mm. Hg or less were achieved in more patients after propranolol than with guanethidine, bethanidine, or methyldopa. Sensitivity to propranolol varies widely, and dosage should be increased gradually. The hypotensive effect often takes six to eight weeks to reach its maximum. Propranolol reduces cardiac output but may also act by reducing the cardiac component of pressor stimuli; as a result the baroreceptors gradually regulate the blood pressure at a lower level. It is contraindicated in patients with obstructive airways disease or in uncompensated heart failure.</description><subject>Average age</subject><subject>Blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiac Output - drug effects</subject><subject>Cardiac output determination</subject><subject>Diuretics</subject><subject>Dosage</subject><subject>Female</subject><subject>Guanethidine - therapeutic use</subject><subject>Guanidines - therapeutic use</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Hypotension - chemically induced</subject><subject>Left ventricular hypertrophy</subject><subject>Male</subject><subject>Methyldopa - therapeutic use</subject><subject>Middle Aged</subject><subject>Papers and Originals</subject><subject>Physical Exertion</subject><subject>Physicians</subject><subject>Placebos</subject><subject>Posture</subject><subject>Pressoreceptors - physiology</subject><subject>Pressure pulses</subject><subject>Propranolol - administration &amp; dosage</subject><subject>Propranolol - adverse effects</subject><subject>Propranolol - therapeutic use</subject><subject>Valsalva Maneuver</subject><issn>0007-1447</issn><issn>0959-8138</issn><issn>1468-5833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1969</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kM9LwzAYhoMoc8zdvAoDD4LY2S8_m4sgw6kg6mGKt5A2qevcmpl06v57WzqmXjyF8Dy838uL0CHEQwDCz9PFbAhDxgkbih3UBcqTiCWE7KJuHMciAkrFPuqHMKu_mIhEctpBHSY4SKBddDrxVlcLW1YDlw9u1kvrK1uGwpWDz6KaDh69W3pdurmbH6C9XM-D7W_eHnoaX01GN9Hdw_Xt6PIuSqmUVYS5sdIAznBqeMZEboy2FmNsQKSGEsqpoCTlJs2BZizhJEuTmHGqiRQxEaSHLtrc5SpdWJPV3byeq6UvFtqvldOF-kvKYqpe3YcCmUACvA443gR4976yoVIzt_Jl3VmBEBwz4Elz5qy1Mu9C8DbfXoBYNduqelsFqtlWNfrR71ZbebPkD5-FyvktxjGRjDBZ86jlRajs15Zr_6a4IIKp--eRehk_3strgRWr_ZPWb1r82-wb41WZyg</recordid><startdate>19690104</startdate><enddate>19690104</enddate><creator>Prichard, B. N. C.</creator><creator>Gillam, P. M. S.</creator><general>British Medical Journal Publishing Group</general><general>British Medical Association</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>19690104</creationdate><title>Treatment of Hypertension with Propranolol</title><author>Prichard, B. N. C. ; Gillam, P. M. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b499t-26de9d12c2bd6c57fddaee222d17bd43464743b6dbf14c5863cb80564a3970373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1969</creationdate><topic>Average age</topic><topic>Blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiac Output - drug effects</topic><topic>Cardiac output determination</topic><topic>Diuretics</topic><topic>Dosage</topic><topic>Female</topic><topic>Guanethidine - therapeutic use</topic><topic>Guanidines - therapeutic use</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Hypotension - chemically induced</topic><topic>Left ventricular hypertrophy</topic><topic>Male</topic><topic>Methyldopa - therapeutic use</topic><topic>Middle Aged</topic><topic>Papers and Originals</topic><topic>Physical Exertion</topic><topic>Physicians</topic><topic>Placebos</topic><topic>Posture</topic><topic>Pressoreceptors - physiology</topic><topic>Pressure pulses</topic><topic>Propranolol - administration &amp; dosage</topic><topic>Propranolol - adverse effects</topic><topic>Propranolol - therapeutic use</topic><topic>Valsalva Maneuver</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prichard, B. N. C.</creatorcontrib><creatorcontrib>Gillam, P. M. S.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prichard, B. N. C.</au><au>Gillam, P. M. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Hypertension with Propranolol</atitle><jtitle>BMJ</jtitle><addtitle>Br Med J</addtitle><date>1969-01-04</date><risdate>1969</risdate><volume>1</volume><issue>5635</issue><spage>7</spage><epage>16</epage><pages>7-16</pages><issn>0007-1447</issn><issn>0959-8138</issn><eissn>1468-5833</eissn><abstract>When used in the treatment of hypertension propranolol is at least of similar potency to bethanidine, guanethidine, and methyldopa. Propranolol does not produce postural or exercise hypotension and it seems that it is often more acceptable to patients than conventional drugs. It usually produces the best control of the supine blood pressure. A series of 109 hypertensive patients was treated with propranolol; in nine the drug was withdrawn. In 92 of the patients a supine or standing blood pressure of 100 mm. Hg or less was achieved. Eighty of the patients had previously been treated with other potent drugs, and close comparisons and prolonged follow-up in 17 patients showed that diastolic pressures of 100 mm. Hg or less were achieved in more patients after propranolol than with guanethidine, bethanidine, or methyldopa. Sensitivity to propranolol varies widely, and dosage should be increased gradually. The hypotensive effect often takes six to eight weeks to reach its maximum. Propranolol reduces cardiac output but may also act by reducing the cardiac component of pressor stimuli; as a result the baroreceptors gradually regulate the blood pressure at a lower level. It is contraindicated in patients with obstructive airways disease or in uncompensated heart failure.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>5761914</pmid><doi>10.1136/bmj.1.5635.7</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1447
ispartof BMJ, 1969-01, Vol.1 (5635), p.7-16
issn 0007-1447
0959-8138
1468-5833
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1981816
source MEDLINE; JSTOR Archive Collection A-Z Listing; PubMed Central
subjects Average age
Blood pressure
Blood Pressure - drug effects
Cardiac Output - drug effects
Cardiac output determination
Diuretics
Dosage
Female
Guanethidine - therapeutic use
Guanidines - therapeutic use
Humans
Hypertension
Hypertension - drug therapy
Hypotension - chemically induced
Left ventricular hypertrophy
Male
Methyldopa - therapeutic use
Middle Aged
Papers and Originals
Physical Exertion
Physicians
Placebos
Posture
Pressoreceptors - physiology
Pressure pulses
Propranolol - administration & dosage
Propranolol - adverse effects
Propranolol - therapeutic use
Valsalva Maneuver
title Treatment of Hypertension with Propranolol
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A45%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Hypertension%20with%20Propranolol&rft.jtitle=BMJ&rft.au=Prichard,%20B.%20N.%20C.&rft.date=1969-01-04&rft.volume=1&rft.issue=5635&rft.spage=7&rft.epage=16&rft.pages=7-16&rft.issn=0007-1447&rft.eissn=1468-5833&rft_id=info:doi/10.1136/bmj.1.5635.7&rft_dat=%3Cjstor_pubme%3E20395359%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1776251687&rft_id=info:pmid/5761914&rft_jstor_id=20395359&rfr_iscdi=true